Gallbladder AdenocarcinomaSymptoms, Doctors, Treatments, Advances & More
Learn About Gallbladder Adenocarcinoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
University Of Arizona Cancer Center
I enjoy traveling, dancing and food. Dr. Shroff is rated as an Elite provider by MediFind in the treatment of Gallbladder Adenocarcinoma. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.
Ohio State Martha Morehouse Outpatient Care
Timothy Pawlik is a Surgical Oncologist practicing medicine in Columbus, Ohio. Dr. Pawlik is rated as an Elite provider by MediFind in the treatment of Gallbladder Adenocarcinoma. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Gallbladder Adenocarcinoma, Cholangiocarcinoma (Bile Duct Cancer), Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.
Texas Health Surgical Specialists
Dr. Kimberly Washington is fellowship-trained in hepato-pancreato-biliary surgery with vast experience in the surgical and non-surgical treatment of liver, pancreas and biliary tract disorders. She uses a variety of techniques, including minimally invasive laparoscopy, endoscopy, ablation and robotic-assisted approaches, in the management of benign pancreatic masses, acute/chronic pancreatitis and pancreatic cysts. She is also trained in the management of hepatocellular carcinoma, cholangiocarcinoma and all liver metastatic diseases. Additionally, she treats benign diseases of the liver and biliary tract, including hepatic adenomas, liver hemangiomas, polycystic liver disease, simple and complex biliary stone disease, and bile duct injuries.Dr. Washington earned her medical degree and completed general surgery residency at the University of Tennessee in Memphis. She then served the Arlington, Texas community as a board-certified general surgeon from 2014 until 2020. In 2020, she returned to training in hepato-pancreato-biliary surgery fellowship at Oregon Health & Science University in Portland.In addition to her dedication to the management of surgical disease, Dr. Washington has also served on a global scale, caring for patients in India, Peru, Guatemala and Kenya. She has and continues to serve on numerous regional and national committees to advance the treatment of hepato-pancreato-biliary diseases. Dr Washington has published peer-reviewed works on areas of special interest, including multi-disciplinary management of colorectal liver metastasis with node-negative primary disease and surgical management of breast cancer liver metastasis, presenting many of these published works at national and international meetings. Through her role as a faculty member with the TCU Burnett School of Medicine, Dr. Washington was recognized in 2024 with the Gachman Endowed Faculty Excellence Award. She is a member of the American College of Surgeons, Americas Hepato-Pancreato-Biliary Association, American Pancreatic Association, Association of Women Surgeons, International Hepato-Pancreato-Biliary Association, Society of Surgical Oncology and Society for Surgery of the Alimentary Tract. Dr. Washington is rated as an Advanced provider by MediFind in the treatment of Gallbladder Adenocarcinoma. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatic Pseudocyst, Pancreatectomy, and Liver Embolization.
Summary: This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.
Summary: This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers. These patients will have already completed all Standard of Care (SOC) treatments (including neoadjuv...